SRSF1-mediated alternative splicing regulates bladder cancer progression and cisplatin sensitivity through HIF1A/BNIP3/mitophagy axis - Wu, Qikai; Yu, Hao; Sun, Huanyou; Lv, Jiancheng; Zhuang, Juntao; Cai, Lingkai; Jiang, Lingjing; Chen, Yuhan; Tao, Yiran; Bai, Kexin; Yang, Haiwei; Yang, Xiao; et al. (Journal of translational medicine, 2025)
Keywords: Alternative splicing; Alternative Splicing - drug effects; Alternative Splicing - genetics; Analysis; Animals; Autophagy - drug effects; Autophagy - genetics; Bladder cancer; Cancer; Care and treatment; Cell Line, Tumor; Cell Movement - drug effects; Cell Proliferation - drug effects; Chemotherapy; Cisplatin - pharmacology; Cisplatin - therapeutic use; Cisplatin resistance; Development and progression; Disease Progression; Drug Resistance, Neoplasm - drug effects; Drug Resistance, Neoplasm - genetics; Female; Gene Expression Regulation, Neoplastic - drug effects; Genetic engineering; Health aspects; Humans; Hypoxia-Inducible Factor 1, alpha Subunit - metabolism; Male; Mice; Mice, Nude; Mitophagy; Patient outcomes; Physiology, Pathological; Prognosis; Proto-Oncogene Mas; Serine-Arginine Splicing Factors - genetics; Serine-Arginine Splicing Factors - metabolism; Signal Transduction - drug effects; SRSF1; Urinary Bladder Neoplasms - drug therapy; Urinary Bladder Neoplasms - genetics; Urinary Bladder Neoplasms - pathology; China; Alternative splicing; Cisplatin resistance; Mitophagy; Bladder cancer; SRSF1